latest news releases from the newsroom
Dobson Communications Corporation
Dobson Communications Announces Lawsuits
OKLAHOMA CITY, Oct. 22, 2004 (PRIMEZONE) -- Dobson Communications Corporation (NASDAQ: DCEL) today announced that, according to press releases, shareholder suits have been filed against the Company alleging, among other matters, that the Company in 2003 and 2004 issued "materially false and misleading" statements about its operations.
Port of Houston Authority
PHA Commission Considers Bayport, Environmental, Financial Matters
HOUSTON, Oct. 22, 2004 (PRIMEZONE) -- The Port of Houston Authority (PHA) commission will consider several recommendations involving contract awards, bids and proposals, professional services and general administrative and operational matters during its public meeting at 1 p.m. on Monday, October 25, 2004 in the 4th floor board room at 111 East Loop North (exit 29 off Loop 610). This is a change from the usual 2 p.m. start time. Chairman Jim Edmonds will preside over the meeting to be attended by Vice Chairman Kase Lawal, Commissioner Steve Phelps, Commissioner Jim Fonteno, Commissioner Jimmy Burke, Commissioner Cheryl Thompson-Draper, and Commissioner Janiece Longoria.
Bull & Lifshitz, LLP
Bull & Lifshitz, LLP Announces Class Action Lawsuit Against TECO Energy Inc. On Behalf Of Investors -- TE
NEW YORK, Oct. 22, 2004 (PRIMEZONE) -- Bull & Lifshitz, LLP announced today that a class action lawsuit has been filed in the United States District Court for the Middle District of Florida on behalf of purchasers of TECO Energy, Inc. ("TECO") (NYSE:TE) securities during the period between October 30, 2001 and February 4, 2003 (the "Class Period"). A copy of the complaint filed in this action is available from the Court, or can be obtained by request from the firm's website at http://www.nyclasslaw.com/infopackage.html.
NIDEK -- US Hyperopia Clinical Study Update -- 9-Month Update
FREMONT, Calif., Oct. 22, 2004 (PRIMEZONE) -- NIDEK, Inc. today announced, 9-month clinical data from its US FDA Hyperopia Clinical Study for the treatment of hyperopia and hyperopic astigmatism. This marks an important milestone in the study protocol, as a total of 248 eyes have been treated, with a total number approved in the study at 300 eyes. Over the last 12 months, NIDEK has worked closely with the FDA on the design, data-collection and evaluation of the clinical study.